News

For women with breast cancer receiving adjuvant endocrine therapy (AET), adherence may depend on socioeconomic status and out-of-pocket costs.

Genetic testing can be used to stratify the risk of a patient experiencing complications during cancer, such as venous thromboembolism (VTE).

Patients with ovarian cancer often experience recurrence which comes with its own challenges and treatments.

The science linking talcum powder and ovarian cancer is still uncertain.

Immunotherapy expert, Dr. Jeffrey Weber, talks about the importance of early intervention for immune-related adverse events.

The National Coalition for Cancer Survivorship recenly celebrated its 30th anniversary.

The SAMfund and Triage Cancer have partnered to offer financial guidance to cancer patients and caregivers.

Survival in patients with lung cancer could be worse when those patients suffer depression symptoms.

Treatment for sexual pain in women who have been affected by cancer is an unmet need in both oncology and gynecology.

In a recent phase III study, the PARP-inhibitor olaparib was shown to improve progression-free survival for patients with BRCA-positive ovarian cancer.

For survivors suffering from chemotherapy-induced cognitive symptoms, known as "chemobrain," new web-based memory and mental exercises could offer relief.

Despite previous thought, working night shifts does not increase the risk of breast cancer.

Stressing self care, a Mei Fu developed an online platform for prevention and treatment of lymphedema.

Dr. Clayton Lau, a prostate cancer expert, discusses the options for patients with early-stage prostate cancer and the importance of staying educated on this disease.

The Society for Gynecologic Oncology (SGO) released a toolkit of case studies and resources on genetic testing for healthcare providers, patients, and their families.

Survivorship expert Jennifer Klemp talks about optimal survivorship care, the contents of a survivorship plan, measurement of progress and the financial considerations.

A recent study found an increased risk of dementia for patients with prostate cancer being treated with ADT, and those patients with the highest risk had been treated with ADT for the longest period of time.

Denosumab is not inferior to zoledronic acid for treatment of skeletal-related events (SREs) for patients with multiple myeloma, according to a phase III study.

Pembrolizumab gains an FDA approval for frontline therapy of non-small cell lung cancer (NSCLC).

Erin Kopp, NP, discusses the vital role that supportive care plays in oncology, especially for aggressive diseases such as lymphoma.

A recent study found that many patients do not read prescription drug information, leading to limited recall of risk information.

Judith Paice, an expert on cancer-related pain. discusses what can go into obtaining medical marijuana.

For patients with HR-positive breast cancer, fulvestrant proved to be better for PFS than anastrozole.

Olaratumab (Lartruvo) has been granted an accelerated approval from the FDA for the treatment of patients with advanced soft tissue sarcoma.

Using the COST questionaire (COmprehensive Score for financial Toxicity), researchers believe they can measure and score a patients risk for financial toxicity on a grading system.

Regorafenib was found to improve overall survival by nearly 3 months for patients with previously treated hepatocellular carcinoma.

Immunotherapy agent atezolizumab approved by FDA for treatment of NSCLC.

The HHS announced a new policy for clinical trial registration and results, hoping to increase patient participation and information sharing.